ELVN
Enliven Therapeutics, Inc.
+1.73 (+3.53%)50.86USD913K成交股數3.7B市值–本益比(近四季)–股價營收比–營收年增(近四季)2026-11-11下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
● 公開市場買進 · ● 公開市場賣出 · 空心 = 10b5-1 預設計畫(事先排程,不代表當下看法)。近一年,只畫 P / S 兩種代碼。
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 29 · 128M · 7 |
| 其中 10b5-1 計畫賣出 | 17 筆 |
| 近 180 天 買進 · 賣出金額 | 0 · 169M |
| 近 180 天 淨額 | −169M |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-17 | 08-19 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S 公開市場賣出(10b5-1) | 1.4K | 59.35 | 82K | 40.0K | SEC |
| 2026-08-17 | 08-19 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M 選擇權執行 | 5.0K | 2.48 | 12K | 30.0K | SEC |
| 2026-08-17 | 08-19 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S 公開市場賣出(10b5-1) | 3.9K | 58.37 | 228K | 26.1K | SEC |
| 2026-08-17 | 08-19 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S 公開市場賣出(10b5-1) | 1.1K | 59.35 | 65K | 25.0K | SEC |
| 2026-08-17 | 08-19 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S 公開市場賣出(10b5-1) | 4.6K | 58.35 | 270K | 41.4K | SEC |
| 2026-08-04 | 08-06 | Derynck Mika K | Director | M 選擇權執行 | 27.6K | 25.28 | 697K | 115K | SEC |
| 2026-08-04 | 08-06 | Derynck Mika K | Director | S 公開市場賣出(10b5-1) | 159K | 60.21 | 9.6M | 0 | SEC |
| 2026-08-04 | 08-06 | Derynck Mika K | Director | M 選擇權執行 | 87.4K | 2.48 | 217K | 87.4K | SEC |
| 2026-08-04 | 08-06 | Derynck Mika K | Director | M 選擇權執行 | 20.5K | 22.47 | 460K | 159K | SEC |
| 2026-08-04 | 08-06 | Derynck Mika K | Director | M 選擇權執行 | 23.4K | 14.85 | 347K | 138K | SEC |
| 2026-07-17 | 07-21 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S 公開市場賣出(10b5-1) | 2.2K | 53.42 | 117K | 25.1K | SEC |
| 2026-07-17 | 07-21 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S 公開市場賣出(10b5-1) | 2.1K | 52.39 | 108K | 27.2K | SEC |
| 2026-07-17 | 07-21 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S 公開市場賣出(10b5-1) | 123 | 53.87 | 7K | 46.1K | SEC |
| 2026-07-17 | 07-21 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S 公開市場賣出(10b5-1) | 231 | 50.05 | 12K | 29.8K | SEC |
| 2026-07-17 | 07-21 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S 公開市場賣出(10b5-1) | 2.6K | 53.38 | 141K | 46.2K | SEC |
| 2026-07-17 | 07-21 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S 公開市場賣出(10b5-1) | 2.6K | 52.32 | 134K | 48.8K | SEC |
| 2026-07-17 | 07-21 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S 公開市場賣出(10b5-1) | 63 | 53.92 | 3K | 25.0K | SEC |
| 2026-07-17 | 07-21 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S 公開市場賣出(10b5-1) | 324 | 49.97 | 16K | 51.7K | SEC |
| 2026-07-17 | 07-21 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M 選擇權執行 | 5.0K | 2.48 | 12K | 30.0K | SEC |
| 2026-07-17 | 07-21 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S 公開市場賣出(10b5-1) | 459 | 51.55 | 24K | 29.3K | SEC |
| 2026-07-17 | 07-21 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M 選擇權執行 | 1.1K | 2.48 | 3K | 52.1K | SEC |
| 2026-07-17 | 07-21 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S 公開市場賣出(10b5-1) | 369 | 51.48 | 19K | 51.4K | SEC |
| 2026-07-06 | 07-08 | Kunkel Lori Anne | Director | S 公開市場賣出(10b5-1) | 5.9K | 50.84 | 299K | 41.9K | SEC |
| 2026-07-06 | 07-08 | Kunkel Lori Anne | Director | S 公開市場賣出(10b5-1) | 4.1K | 49.98 | 205K | 47.8K | SEC |
| 2026-06-22 | 06-24 | OrbiMed Capital GP VII LLC | TenPercentOwner | S 公開市場賣出 | 1.5K | 45.00 | 66K | 219K | SEC |
| 2026-06-22 | 06-24 | OrbiMed Capital GP VII LLC | TenPercentOwner | S 公開市場賣出 | 24.8K | 45.38 | 1.1M | 221K | SEC |
| 2026-06-22 | 06-24 | ORBIMED ADVISORS LLC | TenPercentOwner | S 公開市場賣出 | 46.8K | 45.00 | 2.1M | 6.6M | SEC |
| 2026-06-22 | 06-24 | ORBIMED ADVISORS LLC | TenPercentOwner | S 公開市場賣出 | 1.5K | 45.00 | 66K | 219K | SEC |
| 2026-06-22 | 06-24 | ORBIMED ADVISORS LLC | TenPercentOwner | S 公開市場賣出 | 787K | 45.38 | 35.7M | 6.6M | SEC |
| 2026-06-22 | 06-24 | OrbiMed Capital GP VII LLC | TenPercentOwner | S 公開市場賣出 | 787K | 45.38 | 35.7M | 6.6M | SEC |
| 2026-06-22 | 06-24 | OrbiMed Genesis GP LLC | TenPercentOwner | S 公開市場賣出 | 24.8K | 45.38 | 1.1M | 221K | SEC |
| 2026-06-22 | 06-24 | OrbiMed Capital GP VII LLC | TenPercentOwner | S 公開市場賣出 | 46.8K | 45.00 | 2.1M | 6.6M | SEC |
| 2026-06-22 | 06-24 | ORBIMED ADVISORS LLC | TenPercentOwner | S 公開市場賣出 | 24.8K | 45.38 | 1.1M | 221K | SEC |
| 2026-06-22 | 06-24 | OrbiMed Genesis GP LLC | TenPercentOwner | S 公開市場賣出 | 46.8K | 45.00 | 2.1M | 6.6M | SEC |
| 2026-06-22 | 06-24 | OrbiMed Genesis GP LLC | TenPercentOwner | S 公開市場賣出 | 787K | 45.38 | 35.7M | 6.6M | SEC |
| 2026-06-22 | 06-24 | OrbiMed Genesis GP LLC | TenPercentOwner | S 公開市場賣出 | 1.5K | 45.00 | 66K | 219K | SEC |
| 2026-06-17 | 06-22 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S 公開市場賣出(10b5-1) | 1.1K | 44.74 | 51K | 25.0K | SEC |
| 2026-06-17 | 06-22 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S 公開市場賣出(10b5-1) | 1.3K | 42.83 | 54K | 28.7K | SEC |
| 2026-06-17 | 06-22 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S 公開市場賣出(10b5-1) | 1.2K | 44.75 | 55K | 51.0K | SEC |
| 2026-06-17 | 06-22 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M 選擇權執行 | 5.0K | 2.48 | 12K | 30.0K | SEC |
| 2026-06-17 | 06-22 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S 公開市場賣出(10b5-1) | 3.4K | 43.86 | 149K | 52.2K | SEC |
| 2026-06-17 | 06-22 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S 公開市場賣出(10b5-1) | 1.4K | 42.79 | 59K | 55.6K | SEC |
| 2026-06-17 | 06-22 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | M 選擇權執行 | 6.0K | 2.48 | 15K | 57.0K | SEC |
| 2026-06-17 | 06-22 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S 公開市場賣出(10b5-1) | 2.6K | 43.87 | 114K | 26.1K | SEC |
| 2026-06-15 | 06-17 | ORBIMED ADVISORS LLC | TenPercentOwner | S 公開市場賣出 | 9.1K | 45.02 | 409K | 246K | SEC |
| 2026-06-15 | 06-17 | OrbiMed Capital GP VII LLC | TenPercentOwner | S 公開市場賣出 | 272K | 45.02 | 12.3M | 7.4M | SEC |
| 2026-06-15 | 06-17 | OrbiMed Genesis GP LLC | TenPercentOwner | S 公開市場賣出 | 272K | 45.02 | 12.3M | 7.4M | SEC |
| 2026-06-15 | 06-17 | OrbiMed Genesis GP LLC | TenPercentOwner | S 公開市場賣出 | 9.1K | 45.02 | 409K | 246K | SEC |
| 2026-06-15 | 06-17 | OrbiMed Capital GP VII LLC | TenPercentOwner | S 公開市場賣出 | 9.1K | 45.02 | 409K | 246K | SEC |
| 2026-06-15 | 06-17 | ORBIMED ADVISORS LLC | TenPercentOwner | S 公開市場賣出 | 272K | 45.02 | 12.3M | 7.4M | SEC |
| 2026-06-05 | 06-09 | Kunkel Lori Anne | Director | S 公開市場賣出(10b5-1) | 354 | 35.82 | 13K | 51.9K | SEC |
| 2026-06-05 | 06-09 | Kunkel Lori Anne | Director | S 公開市場賣出(10b5-1) | 1.9K | 35.36 | 66K | 52.2K | SEC |
| 2026-06-05 | 06-09 | Kunkel Lori Anne | Director | S 公開市場賣出(10b5-1) | 7.8K | 34.28 | 267K | 54.1K | SEC |
| 2026-05-18 | 05-20 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M 選擇權執行 | 5.0K | 2.48 | 12K | 30.0K | SEC |
| 2026-05-18 | 05-20 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S 公開市場賣出(10b5-1) | 223 | 41.21 | 9K | 25.0K | SEC |
| 2026-05-18 | 05-20 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S 公開市場賣出(10b5-1) | 1.3K | 40.25 | 52K | 25.2K | SEC |
| 2026-05-18 | 05-20 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S 公開市場賣出(10b5-1) | 3.5K | 39.53 | 137K | 26.5K | SEC |
| 2026-04-17 | 04-21 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S 公開市場賣出(10b5-1) | 2.4K | 47.39 | 115K | 27.4K | SEC |
| 2026-04-17 | 04-21 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S 公開市場賣出(10b5-1) | 140 | 45.81 | 6K | 29.9K | SEC |
| 2026-04-17 | 04-21 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M 選擇權執行 | 5.0K | 2.48 | 12K | 30.0K | SEC |
| 2026-04-17 | 04-21 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S 公開市場賣出(10b5-1) | 2.4K | 48.06 | 117K | 25.0K | SEC |
| 2026-03-25 | 03-27 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S 公開市場賣出(10b5-1) | 40.0K | 35.10 | 1.4M | 25.0K | SEC |
| 2026-03-25 | 03-27 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M 選擇權執行 | 40.0K | 2.48 | 99K | 65.0K | SEC |
| 2026-03-17 | 03-19 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M 選擇權執行 | 5.0K | 2.48 | 12K | 30.0K | SEC |
| 2026-03-17 | 03-19 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S 公開市場賣出(10b5-1) | 5.0K | 27.76 | 139K | 25.0K | SEC |
| 2026-03-10 | 03-11 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S 公開市場賣出(10b5-1) | 10.1K | 30.19 | 306K | 25.0K | SEC |
| 2026-03-10 | 03-11 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M 選擇權執行 | 10.1K | 2.48 | 25K | 35.1K | SEC |
| 2026-03-09 | 03-11 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M 選擇權執行 | 29.9K | 2.48 | 74K | 54.9K | SEC |
| 2026-03-09 | 03-11 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S 公開市場賣出(10b5-1) | 29.9K | 30.02 | 897K | 25.0K | SEC |
| 2026-03-06 | 03-10 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | S 公開市場賣出 | 10.0K | 29.58 | 296K | 51.0K | SEC |
| 2026-02-17 | 02-19 | Heyman Richard A. | Director | S 公開市場賣出(10b5-1) | 1.2K | 26.18 | 32K | 22.6K | SEC |
| 2026-02-17 | 02-19 | Collins Helen Louise | CHIEF MEDICAL OFFICER | M 選擇權執行 | 45.0K | 2.48 | 112K | 70.0K | SEC |
| 2026-02-17 | 02-19 | Collins Helen Louise | CHIEF MEDICAL OFFICER | S 公開市場賣出(10b5-1) | 45.0K | 26.17 | 1.2M | 25.0K | SEC |
| 2026-02-12 | 02-17 | Patel Anish | CHIEF OPERATING OFFICER | A 獲配股票 | 20.0K | – | – | 20.0K | SEC |
| 2026-02-12 | 02-17 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | A 獲配股票 | 18.8K | – | – | 18.8K | SEC |
| 2026-02-12 | 02-17 | Hohl Benjamin | CHIEF FINANCIAL OFFICER | A 獲配股票 | 25.0K | – | – | 61.0K | SEC |
| 2026-02-12 | 02-17 | Collins Helen Louise | CHIEF MEDICAL OFFICER | A 獲配股票 | 25.0K | – | – | 25.0K | SEC |
| 2026-02-06 | 02-10 | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S 公開市場賣出(10b5-1) | 5.0K | 29.04 | 145K | 740K | SEC |
| 2026-01-20 | 01-22 | Heyman Richard A. | Director | S 公開市場賣出(10b5-1) | 718 | 26.96 | 19K | 23.9K | SEC |
| 2026-01-20 | 01-22 | Heyman Richard A. | Director | S 公開市場賣出(10b5-1) | 512 | 26.46 | 14K | 24.6K | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 · 最新 2026-06-30
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| FMR LLC | 10.0M | 509M | +3.2M (+47%) | 加碼 |
| ORBIMED ADVISORS LLC | 6.8M | 344M | −1.2M (-15%) | 減碼 |
| Polar Capital Holdings Plc | 6.4M | 326M | +1.4M (+27%) | 加碼 |
| BlackRock, Inc. | 4.4M | 221M | +675K (+18%) | 加碼 |
| Vestal Point Capital, LP | 4.0M | 203M | +750K (+23%) | 加碼 |
| Commodore Capital LP | 3.3M | 166M | 不變 | 持平 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.6M | 130M | +401K (+18%) | 加碼 |
| 城堡 CITADEL ADVISORS LLC | 2.1M | 105M | +325K (+19%) | 加碼 |
| Fairmount Funds Management LLC | 1.9M | 94.2M | 不變 | 持平 |
| Siren, L.L.C. | 1.8M | 90.1M | +1.0M (+138%) | 加碼 |
| Bellevue Group AG | 1.5M | 75.6M | −831K (-36%) | 減碼 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.4M | 71.4M | +341K (+32%) | 加碼 |
| First Light Asset Management, LLC | 1.4M | 69.1M | +1.2M (+574%) | 加碼 |
| STATE STREET CORP | 1.2M | 61.6M | +123K (+11%) | 加碼 |
| Pictet Asset Management Holding SA | 1.2M | 59.0M | +232K (+25%) | 加碼 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.1M | 55.0M | 新進 | 新進 |
| NOVO HOLDINGS A/S | 1.0M | 50.8M | −280K (-22%) | 減碼 |
| First Turn Management, LLC | 954K | 48.4M | +331K (+53%) | 加碼 |
| SAMLYN CAPITAL, LLC | 913K | 46.3M | 新進 | 新進 |
| BAKER BROS. ADVISORS LP | 905K | 45.9M | 不變 | 持平 |
| Candriam S.C.A. | 906K | 45.9M | +312K (+52%) | 加碼 |
| Tri Locum Partners LP | 867K | 44.0M | 新進 | 新進 |
| ALLIANCEBERNSTEIN L.P. | 896K | 35.1M | +124K (+16%) | 加碼 |
| DIMENSIONAL FUND ADVISORS LP | 671K | 34.1M | −10.3K (-2%) | 減碼 |
| Assenagon Asset Management S.A. | 613K | 31.1M | 新進 | 新進 |
持有機構數近 12 季
每季 13F 申報中持有本股的機構家數;綠柱 = 比上季少。機構數是「有多少人在船上」,不是「買了多少」。
| 持有機構 · 季變化 | 212 +41 |
|---|---|
| 新進 / 出清 / 加碼 / 減碼 | 63 / 22 / 84 / 46 |
| 機構合計持股 · 佔流通股 | 80.4M · 100.0% |
| 合計季末市值 | 3.9B |
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)· 最新 2026-08-31
空單佔流通股近 13 個月
FINRA 每月兩次結算的空單餘額佔流通股數的比例,近 13 個月。滑到柱子看股數與回補天數。
最新一期
| 空單股數 | 8.6M |
|---|---|
| 與上期比 | +4.1% |
| 佔流通股數 | 11.74% |
| 日均成交量 | 777K |
| 回補天數 | 11.1 天 |
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|---|---|---|---|---|
| 2026-08-31 | 8.6M | +4.1% | 11.74% | 777K | 11.1 |
| 2026-08-14 | 8.3M | +1.3% | 11.27% | 1.3M | 6.3 |
| 2026-07-31 | 8.2M | -5.8% | 11.13% | 712K | 11.4 |
| 2026-07-15 | 8.7M | +1.5% | 11.81% | 919K | 9.4 |
| 2026-06-30 | 8.5M | +57.1% | 11.64% | 2.8M | 3.1 |
| 2026-06-15 | 5.4M | +4.1% | 7.41% | 2.1M | 2.6 |
| 2026-05-29 | 5.2M | +1.8% | 7.12% | 597K | 8.7 |
| 2026-05-15 | 5.1M | -2.9% | 6.99% | 637K | 8.1 |
| 2026-04-30 | 5.3M | -1.9% | 7.20% | 769K | 6.9 |
| 2026-04-15 | 5.4M | -11.2% | 7.33% | 1.3M | 4.3 |
| 2026-03-31 | 6.1M | -26.3% | 8.26% | 2.1M | 2.9 |
| 2026-03-13 | 8.2M | +3.0% | 11.21% | 779K | 10.5 |
| 2026-02-27 | 8.0M | -1.2% | 10.89% | 651K | 12.3 |
| 2026-02-13 | 8.1M | +2.6% | 11.03% | 720K | 11.2 |
| 2026-01-30 | 7.9M | -14.1% | 10.74% | 997K | 7.9 |
| 2026-01-15 | 9.2M | +10.3% | 12.51% | 2.2M | 4.2 |
| 2025-12-31 | 8.3M | +2.5% | 11.35% | 701K | 11.9 |
| 2025-12-15 | 8.1M | +1.4% | 11.07% | 827K | 9.8 |
| 2025-11-28 | 8.0M | +2.6% | 10.91% | 543K | 14.7 |
| 2025-11-14 | 7.8M | +0.1% | 10.64% | 752K | 10.4 |
| 2025-10-31 | 7.8M | +21.2% | 10.62% | 428K | 18.2 |
| 2025-10-15 | 6.4M | +12.7% | 8.77% | 414K | 15.5 |
| 2025-09-30 | 5.7M | +17.4% | 7.78% | 694K | 8.2 |
| 2025-09-15 | 4.9M | -0.7% | 6.63% | 477K | 10.2 |
| 2025-08-29 | 4.9M | -1.1% | 6.68% | 475K | 10.3 |
| 2025-08-15 | 4.9M | -2.6% | 6.75% | 377K | 13.1 |